# A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

> **NCT04280718** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **argenx** · enrollment: 229 (actual)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

## Interventions

- **BIOLOGICAL:** Efgartigimod PH20 SC

## Key facts

- **NCT ID:** NCT04280718
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-18
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04280718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04280718, "A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04280718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*